C
Cheryl A. London
Researcher at Tufts University
Publications - 128
Citations - 5180
Cheryl A. London is an academic researcher from Tufts University. The author has contributed to research in topics: Cancer & Toceranib. The author has an hindex of 36, co-authored 125 publications receiving 4408 citations. Previous affiliations of Cheryl A. London include Ohio State University & University of California, Davis.
Papers
More filters
Journal ArticleDOI
The dog as a cancer model.
Chand Khanna,Kerstin Lindblad-Toh,David M. Vail,Cheryl A. London,Philip J. Bergman,Lisa G. Barber,Matthew Breen,Barbara E. Kitchell,Elizabeth A. McNeil,Jaime F. Modiano,Steven Niemi,Kenine E. Comstock,Elaine A. Ostrander,Susan V. Westmoreland,Stephen J. Withrow +14 more
TL;DR: Rather than arguing for the importance of long-term database funding by granting agencies, BIND’s saga in fact argues for greater caution and more demanding oversight when these agencies elect to fund a database‘s initial development.
Journal ArticleDOI
Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document
TL;DR: The human response evaluation criteria in solid tumours is used as a framework to establish standard procedures for response assessment in canine solid tumour assessment that is meant to be easy to use, repeatable and applicable across a variety of clinical trial structures in veterinary oncology.
Journal ArticleDOI
Feline lymphoma in the post-feline leukemia virus era
TL;DR: A significant decrease in the importance of FeLV-associated types of lymphoma in cats is confirmed and Associations of intestinal lymphoma and inflammatory bowel disease and diet should be further considered.
Journal ArticleDOI
Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)--a Veterinary Cooperative Oncology Group (VCOG) consensus document.
TL;DR: These guidelines are intended only for use in dogs, where peripheral lymphadenopathy represents the principal component of their disease and as such do not critically assess extranodal disease (e.g., primary cutaneous, central nervous system, gastrointestinal).
Journal ArticleDOI
Canine osteosarcoma: a naturally occurring disease to inform pediatric oncology.
TL;DR: Clinical and molecular evidence suggests that human and canine OSA share many key features, including tumor location, presence of microscopic metastatic disease at diagnosis, development of chemotherapy-resistant metastases, and altered expression/activation of several proteins, supporting the notion that these diseases are similar at the molecular level.